Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. Biogen markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis, FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy.

Employee Rating

3.5More
TypePublic
HQCambridge, US
Founded1978
Size (employees)7,300 (est)
Websitebiogen.com
Biogen was founded in 1978 and is headquartered in Cambridge, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Biogen

Michel Vounatsos

Michel Vounatsos

CEO
Susan Alexander

Susan Alexander

EVP
Jeffrey Capello

Jeffrey Capello

EVP
Michael Ehlers

Michael Ehlers

EVP
Ginger Gregory

Ginger Gregory

EVP
Chirfi Guindo

Chirfi Guindo

EVP
Show more

Biogen Office Locations

Biogen has an office in Cambridge
Cambridge, (HQ)
225 Binney St
Show all (1)
Report incorrect company information

Biogen Financials and Metrics

Biogen Revenue

Biogen's revenue was reported to be $11.45 b in FY, 2016 which is a 6.4% increase from the previous period.
USD

Revenue (Q1, 2017)

2.8b

Net income (Q1, 2017)

747.5m

EBIT (Q1, 2017)

1.0b

Market capitalization (4-Dec-2018)

65.0b

Closing stock price (4-Dec-2018)

322.7

Cash (31-Mar-2017)

924.0m
Biogen's current market capitalization is $65 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

6.9b9.7b10.8b11.4b

Revenue growth, %

40%11%6%

General and administrative expense

1.9b

R&D expense

2.0b
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

2.4b2.5b2.6b2.6b2.8b2.7b2.9b3.0b2.8b

General and administrative expense

576.6m570.4m560.4m491.9m477.8m497.3m492.4m462.7m499.1m

R&D expense

447.3m417.2m460.5m490.7m519.9m437.3m473.1m529.0m423.4m

Operating expense total

1.0b987.6m1.0b982.6m997.7m934.6m965.5m991.7m922.5m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

602.6m1.2b1.3b2.3b

Accounts Receivable

824.4m1.3b1.2b1.4b

Inventories

659.0m804.0m893.4m1.0b

Current Assets

3.2b4.7b6.7b8.7b
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

863.2m1.2b1.5b1.3b4.1b1.1b1.4b2.1b924.0m

Accounts Receivable

1.0b1.1b1.4b1.3b1.3b1.4b1.3b1.5b1.5b

Inventories

715.9m753.1m825.3m865.7m918.9m964.6m996.4m1.0b921.6m

Current Assets

3.9b4.4b5.3b5.6b9.3b7.2b7.4b8.1b6.9b
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

1.9b2.9b3.6b3.7b

Depreciation and Amortization

688.2m600.4m682.7m

Inventories

(240.0m)(190.0m)(170.0m)(165.6m)
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

723.1m856.1m820.2m924.8m1.0b969.2m1.0b1.0b747.5m

Inventories

865.7m918.9m964.6m996.4m1.0b921.6m

Accounts Payable

282.7m251.2m271.3m225.9m274.0m316.4m
USDY, 2017

Revenue/Employee

379.8k

Financial Leverage

1.8 x
Show all financial metrics

Biogen Operating Metrics

Biogen's Training Provided, no. of people was reported to be 40 k in FY, 2016.
FY, 2016

Phase I Trials Products

4

Phase II Trials Products

10

Phase III Trials Products

2

Training Provided, no. of people

40 k
Show all operating metrics

Biogen Acquisitions / Subsidiaries

Acquired CompanyDateDeal Size
AliveGenJuly 25, 2018$27.50 m
Karyopharm TherapeuticsJanuary 25, 2018$10 m
Report incorrect company information

Biogen Online and Social Media Presence

Embed Graph
Report incorrect company information

Biogen News and Updates

Biogen Exercises Option with Ionis to Develop and Commercialize Investigational Treatment BIIB067 for a Subtype of Familial Amyotrophic Lateral Sclerosis (ALS) Based on Positive Phase 1 Data

CAMBRIDGE, Mass. and CARLSBAD, Calif., Dec. 06, 2018 (GLOBE NEWSWIRE) -- Biogen Inc (Nasdaq: BIIB) and Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that Biogen exercised its option to obtain from Ionis a worldwide, exclusive, royalty-bearing license to develop and commercialize BIIB0…

CD Antigen Cancer Therapy Global Market 2018 Top Key Players – AryoGen Biopharma , Biocad , Biogen Idec,  Celltrion , Genentech and Forecast to 2025

Wiseguyreports.Com Added New Market Research Report On -“Global CD Antigen Cancer Therapy Market 2018 Top Key Players, Production , Growth and Future Demand Forecast to 2025 ”. Posted via Industry Today. Follow us on Twitter @IndustryToday

Global Spinal Muscular Atrophy Market Forecast Report 2017-2026 Featuring Biogen, Roche, Novartis & Cytokinetics

DUBLIN, Nov. 26, 2018 /PRNewswire/ -- The "Spinal Muscular Atrophy Market Global Forecast by Countries, Drugs, and Companies" report has been added to ResearchAndMarkets.com's offering. The global spinal muscular atrophy market and provides an all-encompassing analysis of the key growth...

New Research on Neurodegenerative Drugs Market 2023 Overview and Analysis, Focusing on top key players - Novartis International AG, Pfizer Inc, Merck Serono, Biogen Idec, Teva Pharmaceutical Industries Ltd and others

The report titled Global Neurodegenerative Drugs market studies the dynamics and growth prospects of the global Neurodegenerative Drugs market. The report evaluates the growth exhibited by the market in the historical study period and includes information covering definition, classification, industr…

The Global Market for Antisense & RNAi Therapeutics is Projected to Grow at a CAGR of 8.67% During 2019-2023, Led by Alnylam Pharmaceuticals, Bausch Health, Biogen, and Sarepta Therapeutics

DUBLIN, Nov 19, 2018 /PRNewswire/ -- The "Global Antisense and RNAi Therapeutics Market 2019-2023" report has been added to ResearchAndMarkets.com's offering. The Global Antisense and RNAi Therapeutics Market is projected to grow at a CAGR of 8.67% during the period 2019-2023. The report...

Biogen and Eisai Announce Presentation of Detailed Analyses from the Phase 1b Long-Term Extension Study of Aducanumab at Clinical Trials on Alzheimer’s Disease (CTAD)

Three- and four-year data continued to show reduction in amyloid plaque and to suggest a slowing of the rate of clinical decline in patients
Show more
Report incorrect company information

Biogen Blogs

Biogen Advances Research to Improve Outcomes for Patients With Multiple Sclerosis

Evidence supports potential of serum neurofilament light (sNfL) as clinically useful biomarker in MS; Biogen and Siemens Healthineers collaborate to develop sNfL blood test Real-world data add to the large body of evidence establishing the long-term effectiveness of TECFIDERA and TYSABRI, including

New SPINRAZA® (nusinersen) Data Presented at Annual Congress of the World Muscle Society Demonstrate Benefits in Treating Presymptomatic Infants with Spinal Muscular Atrophy

NURTURE study participants were alive and did not require permanent ventilation, in contrast to natural history of spinal muscular atrophy (SMA) Study participants achieved motor milestones with 100 percent sitting independently and 88 percent able to walk Additional data feature biomarkers as an

Biogen to Host Investor Webcasts from Clinical Trials on Alzheimer’s Disease Meeting on October 25-26, 2018

Cambridge, Mass. – October 4, 2018 – Biogen (Nasdaq: BIIB) today announced it will host live webcasts of its oral presentation and keynote address, as well as a Q&A session related to its Alzheimer’s disease investigational therapies, at the upcoming Clinical Trials on Alzheimer’s Disease annual

Biogen to Present Data from its Neurology Pipeline at the 2018 International Congress of Parkinson’s Disease and Movement Disorders (MDS)

CAMBRIDGE, Mass., Oct. 03, 2018 (GLOBE NEWSWIRE) -- Data to be presented from the BIIB092 program for progressive supranuclear palsy and BIIB054 program for Parkinson’s disease highlight Biogen’s commitment to furthering movement disorders research Biogen’s Phase 2 PASSPORT study of BIIB092 for PSP

Biogen Highlights at ECTRIMS 2018 Data on Its Industry-Leading Multiple Sclerosis Portfolio and a Range of Initiatives Aimed at Transforming Patient Care

New research further supports the long-term efficacy and well-characterized safety of leading MS products N ovel data generation initiatives aim to improve outcomes and support the continued move toward precision medicine in MS CAMBRIDGE, Mass., Oct. 02, 2018 (GLOBE NEWSWIRE) -- At the 34th

Biogen to Report Third Quarter 2018 Financial Results October 23, 2018

Cambridge, Mass.— Biogen Inc. (Nasdaq:BIIB) today announced it will report third quarter 2018 financial results Tuesday, October 23, 2018, before the financial markets open.  Following the release of the financials, the Company will host a live webcast with Biogen management from 8:00-9:00 am ET.

Biogen Company Life and Culture

Report incorrect company information

Biogen Frequently Asked Questions

  • When was Biogen founded?

    Biogen was founded in 1978.

  • Who are Biogen key executives?

    Biogen's key executives are Michel Vounatsos, Susan Alexander and Jeffrey Capello.

  • How many employees does Biogen have?

    Biogen has 7,300 employees.

  • What is Biogen revenue?

    Latest Biogen annual revenue is $11.4 b.

  • What is Biogen revenue per employee?

    Latest Biogen revenue per employee is $1.6 m.

  • Who are Biogen competitors?

    Competitors of Biogen include Regeneron Pharmaceuticals, Gilead Sciences and Amgen.

  • Where is Biogen headquarters?

    Biogen headquarters is located at 225 Binney St, Cambridge.

  • Where are Biogen offices?

    Biogen has an office in Cambridge.

  • How many offices does Biogen have?

    Biogen has 1 office.